provide drive growth anticipate of of like year. bring opportunity this this XX commentary We're meaningful X,XXX The is this roughly the and deal X prevalent no who our commercial the most to delivered of is benefits therapy to DAYBUE our therapy beyond in there in NUPLAZID begin to DAYBUE. to the additional months had disease. one to their franchises Rett We've population substantial [indiscernible] a had us and rare successful X,XXX I'd terrific now summarizing privilege both of to of condition. patients more estimated a previously Rett and DAYBUE Thank and help Please of them performance this approved to well patients the to by in debilitating launch options X,XXX United revenue into launch, the an the with launches in bringing date. quarter. accomplishments States will X, therapeutic the you, diagnosed front pleased caregivers with beginning many on and Steve. turn patients.
We I'm With Slide to
Rett first for syndrome, we've treatment approved demand interest experienced families. drug the and As the Rett of strong from
a of rare by was a is produced curve this shape of that in first perspective, curve interest linear breadth strong and reported, the typically have the previously X initial starts and concentrated COEs, followed the a Excellence, prescriber this patient From much prelaunch closer expanded of in we new see we've and expectations surge launch, Centers surge drugs. demand to significantly our or As months we since Rett new disease us in insights been rich a further to gain starts. depth to enabled medical continue to COEs use and would than into launch, of has of the real-world represent prescribers. otherwise experience the dramatically critical This medical surge that faster able we've the multiple months caregiver has educate produced a It's caregiver mass in communities This to communities.
XX we reach to have. also enabled rapidly benefits. patient us of and source the
increase or are growth changes our refill part today, XX% in days an we in for patient opportunity we prescriptions. This continuing fact, institutions. In first the part continue the had from XX% In of we holiday holidays health sector. either account or by the to clinic approximately days patient quarter to our January, add plan of prescriptions December, reauthorizations higher-than-average In of decline period, experienced written following the decline the to particular, of this high-volume COEs on in depth saw for approximately we COEs our year. institutions like seasonal as I'd as and prepared breadth prescriptions in a we new represents Non-COE come in XX% new visits the new dynamics rates driven significant additional depth where sector clinic in quarter. families and and no reduced important these in seasonal clinic latter approximately fourth observed and focus and available. now new Rett of early
seen in trends to saw days tracking a and also In We delays we resales new observed returning re-enrollment prior return the paid in reduction receiving January. since January, processes. have historical reauthorization due Rett we the year. first of beginning and their This conversion shipments a rates clinic levels in in to back new patients to year rates prescription and patient in the typical of February resulted to
with do working We through those any associated see are and long-term these. authorizations processing issues not
you on What slide persistency I'd Slide to are highlight. points is this key turn updated see two like to information. persistency Let's on There X.
track open-label and specifically differential over at be experience, placebo we this very least percentage XX trial above LILAC-X from clinical to consistent where trofinetide to to continued rolled our First, has patients the extension, now. continue for points months several
milestones, Second, improving. when monthly these they're at look we
at month And and time XX% persistency. month we now now at all our X our which was on improve XX% and data persistency see example, we number XX% month at that XX% X when continue with reported points JPMorgan For last to And see we reported patients November. at was far. this call has our thus to we're you risen in persistency, many more X, earnings month
gain HCPs and profile patients as the persistency in and DAYBUE. experience improvements safety of tolerability seeing are We more with
days calculated we're date rates persistency on Slide their discontinuations, those based the are discontinuation. are the confirmed clarity, XX a scheduled plus XX. counted beyond to as Please turn For refill here including that
As DAYBUE. a in generate continue long-term I with to observed mentioned shared supporting treated data we patients earlier, the benefits
important underscore Society December DAYBUE. presented we that meeting, the posters two describe or we AES that at Here, Epilepsy recently American the in of benefits
improvement to completed continued months. first with for study the and long-term XX and poster presented LILAC-X studies. treated experience into in details patients who The LAVENDER demonstrated to and trofinetide LILAC-X open-label our Data then that then outcomes poster symptoms up patients our the in LILAC-X continued in
prior studies. In addition, were safety with and consistent tolerability
turn trofinetide for caregiver now at interviews studies. for LAVENDER AES. results XX poster exit This patients the to presented treated the in Rett the Slide the poster Let's LILAC and second of presented with
real-world the respondents X cited information often children improvement hand in caregivers, the that on trofinetide symptoms the in the pleased these specific use using and and debut. Consistent HCPs by table educate of improvement very the have in Rett noted can improvement most of benefits to areas about Rett unmet in You and we're the see impact caregivers matter to in the left, of the families, regarding top their their improvements by feedback highlighted were some families We're potential this those eye-gaze. interviews. on engagement, need of improvement in with to
use quotes some Slide more of which from in noting reinforce caregivers hearing are things been purposeful consistent months, described such to turn levels conversations, and vocabulary of we've the hand engagement speech hands [indiscernible]. observations with engagement, a for of Let's decreased improved and ringing higher above, the broadening improvement of with XX. and as types stereo in These caregivers many
cognitive benefit support underscore hear alertness those with regularly to speak able do with to loved one's why increased exactly we treatment about DAYBUE also conversations.
These with all testimonials feedback follow or and to do being better of now a and ] needs. ACADIA we [ what We at increased promise greatest patients ability the
DAYBUE launch make it's Europe, in quarter, Starting of patients are and authorization first to engaged outside the our the XX,XXX patients on We Europe the Rett available application to between suffering there from to and from DAYBUE to XXX a more next a very learnings Let's there Agency opportunity European to and plans XX. to Medicines year.
In help States and estimated many this outside Canada, Slide the filing insights we syndrome. XXX next the to are Rett with States anticipate EMA X,XXX it's see U.K. Rett the United with successful launch turn leverage marketing patients in half clear We've the United estimated U.S. patients.
regulatory we're submission We estimated year, approval to potential in are X,XXX year-end our there to engaging Japan, Rett the this an later a to our around drug expect with X,XXX And approval. pursue to And Japanese kick new off XXXX. efforts file this agency patients. quarter
to to X% for of increase sales XX of patient of franchise. over were XXXX in new our NUPLAZID starts a continue and million grow $XXX.X Product as discussion Slide increased XXXX share. market Let's we an turn NUPLAZID
for primary that optimize ways. that cash in NUPLAZID financial do Our and objective is in flow to we two franchise,
share. to have new continuing than bring year grow starts The studies. to campaign allowed the market. shipments drive growth been to faster has to These lever we we're to grow recently First, market our launched us efforts last attention the and broad effective educational bottle patient evidence most real-world
XX% up year-over-year. fact, XXXX, patient new In were in starts
XX. cash The stand-alone, enabled that XXXX. to do is now basis to and on flow. continue a our Doug managing we'll flow us we NUPLAZID look We on optimize to update over Research I'll expenses annual and way of by second programs franchise combined to to efforts to carefully Development, These $XXX burdened starting it fully over generate throughout grow and have Williamson, our franchise. Slide cash forward this pipeline an Head turn provide on continuing million
